None listed
Conditions
Interventions
Others : Patients who decided to receive crizotinib therapy after being confirmed as ROS1 positive NSCLC patients detected by either fluorescence in situ hybridization, reverse transcriptionquantitati
Sponsors
Asan Medical Center
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients who were diagnosed as locally advanced or metastatic NSCLC by histologic or cytologic confirmation 2. Patients who were diagnosed as histologically or cytologically ROS1 positive adenocarcinoma 3. Patients who are to initiate crizotinib treatment for NSCLC But patients who are already under treatment with crizotinib for ROS1-rearranged adenocarcinoma is eligible to the study 4. Male or female adult patients aged 19 years old and above 5. The patients who provide written informed consent for the study
Exclusion criteria
Exclusion criteria: 1. Patients who have already been treated with cirzotinib(ALK inhibitor) 2. Patients whose medical records are not available for review
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Objective response rate (ORR) | — |
Secondary
| Measure | Time frame |
|---|---|
| Duration of Response (DR), Disease Control Rates (DCR), Time To Progression (TTP), Progression-free-survival (PFS), overall survival(OS);Intracranial-objective response rate (IC-ORR), Intracranial-Time To Progression (IC-TTP), extracranial-Time To Progression (EC-TTP),;Clinicopathologic characteristics;Diagnostic efficacy of liquid biopsy (cell-free RNA and circulating tumor cell);Response rate of crizotinib by ROS1 fusion partner genes;Safety | — |
Countries
Korea, Republic of
Contacts
Public ContactCHANG-MIN CHOI
Asan Medical Center
Outcome results
None listed